Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases.
| Autor: | Harlid S; Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden., Van Guelpen B; Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.; Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden., Qu C; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Gylling B; Department of Medical Biosciences, Pathology Unit, Umeå University, Umeå, Sweden., Aglago EK; Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France., Amitay EL; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany., Brenner H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Buchanan DD; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia.; Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Victoria, Australia., Campbell PT; Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, USA., Cao Y; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA.; Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, USA.; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA., Chan AT; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA., Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg (UCCH), Hamburg, Germany., Drew DA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Figueiredo JC; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., French AJ; Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Gallinger S; Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada., Giannakis M; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Giles GG; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia., Gunter MJ; Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France., Hoffmeister M; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hsu L; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Biostatistics, University of Washington, Seattle, Washington, USA., Jenkins MA; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia., Lin Y; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Moreno V; Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.; ONCOBEL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain., Murphy N; Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France., Newcomb PA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; School of Public Health, University of Washington, Seattle, Washington, USA., Newton CC; Department of Population Science, American Cancer Society, Atlanta, Georgia, USA., Nowak JA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Obón-Santacana M; Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.; ONCOBEL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain., Ogino S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Potter JD; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; School of Public Health, University of Washington, Seattle, Washington, USA.; Research Centre for Hauora and Health, Massey University, Wellington, New Zealand., Song M; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA., Steinfelder RS; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Sun W; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Thibodeau SN; Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Toland AE; Departments of Cancer Biology and Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA., Ugai T; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Um CY; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Woods MO; Memorial University of Newfoundland, Discipline of Genetics, St. John's, Canada., Phipps AI; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Epidemiology, University of Washington, Seattle, Washington, USA., Harrison T; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Epidemiology, University of Washington, Seattle, Washington, USA., Peters U; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Epidemiology, University of Washington, Seattle, Washington, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of cancer [Int J Cancer] 2022 Aug 01; Vol. 151 (3), pp. 348-360. Date of Electronic Publication: 2022 Apr 22. |
| DOI: | 10.1002/ijc.34015 |
| Abstrakt: | Diabetes is an established risk factor for colorectal cancer. However, colorectal cancer is a heterogeneous disease and it is not well understood whether diabetes is more strongly associated with some tumor molecular subtypes than others. A better understanding of the association between diabetes and colorectal cancer according to molecular subtypes could provide important insights into the biology of this association. We used data on lifestyle and clinical characteristics from the Colorectal Cancer Family Registry (CCFR) and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), including 9756 colorectal cancer cases (with tumor marker data) and 9985 controls, to evaluate associations between reported diabetes and risk of colorectal cancer according to molecular subtypes. Tumor markers included BRAF and KRAS mutations, microsatellite instability and CpG island methylator phenotype. In the multinomial logistic regression model, comparing colorectal cancer cases to cancer-free controls, diabetes was positively associated with colorectal cancer regardless of subtype. The highest OR estimate was found for BRAF-mutated colorectal cancer, n = 1086 (OR (© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text